{
  "index": 277,
  "prompt": "\nGiven the following scenario, first consider the actors and stakeholders involved then extrapolate and present as a timeline how the situation might evolve. \nConsider as many multiple possibilities based on possible responses which are to be represented as branches on this timeline. \n\nMake sure that the timeline generated are of **HIGH QUALITY** as defined by the following criteria\n* Plausibility: Economic, financial and political plausibility of each path on the timeline \n    * High: Events are strongly supported by current macro data, institutional knowledge, and have strong analogs in history or system models (e.g., “monetary tightening leads to recession, triggering a political backlash”)\n    * Low: Contains major violations of cause-effect logic, timing, or real-world behavior (e.g., hyperinflation causes interest rate cuts during a currency collapse)\n* Novelty: Creativity/originality in the nodes and paths, are they something you may have overlooked?\n    * High: Demonstrates expert-level creative reasoning. Identifies counterintuitive paths, rare risks, or hidden feedback loops. May challenge conventional wisdom in a grounded way (e.g., “trade war accelerates global realignment of semiconductors via Middle East sovereign wealth capital”). Could lead to edge in investment or policy thinking.\n    * Low: Timeline is linear, obvious, or closely tracks past headlines or boilerplate analysis. No creative branching or exploration.\n* Elaboration: How specific and refined are the occurrences represented by the nodes?\n    * High: Timeline reads like a mini-case study. Each node could stand alone as an actionable insight. Paths show feedback loops, strategic responses, and sector-level granularity (e.g., “Volkswagen reallocates $1.2B R&D from EVs to hybrid tech in response to rare earth prices”). Truly investment-grade thinking.\n    * Low: Nodes are generic (e.g., “market reacts”, “tensions rise”) with no detail on mechanisms, actors, or consequences. Lacks causal clarity.\n* Actionable: Can this timeline inform specific investment actions or hedging strategies?\n    * High: Timeline includes sector impacts, asset class consequences, or opportunities (e.g., “short EU auto suppliers”, “long U.S. rail freight”)\n    * Low: Insightful narrative, but no clear link to tradable instruments or positioning ideas\n\nKeep to the output format below where ascii is used to represent the timeline as a tree. \n\n[Example of Scenario]\nWASHINGTON/DETROIT, April 29 (Reuters) - U.S. President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday with a mix of credits and relief from other levies on materials, and his trade team touted its first deal with a foreign trading partner.\nThe developments helped eased some investor worries about the erratic trade policies of Trump as the president visited Michigan, a cradle of the U.S. auto industry, just days before a fresh set of 25% import taxes was set to kick in on automotive components.\n\n[Example of Output]\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Event\",\n  \"description\": \"German inflation data released at 2.2%\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"ECB maintains dovish stance\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB maintains dovish stance, keeps rates low\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"German banks increase lending\",\n          \"description\": \"German banks benefit from low rates, increase lending\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Euro weakens\",\n          \"description\": \"Euro weakens, boosting exports\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Moderate industrial growth\",\n          \"description\": \"German industry reports moderate growth\"\n        },\n        {\n          \"id\": \"T1A1.4\",\n          \"title\": \"Bundesbank caution\",\n          \"description\": \"Bundesbank signals caution on inflation\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Industry adapts to inflation\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Companies pass on higher costs; unions request wage hikes; consumer shifts emerge\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Markets stabilize\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Eurozone growth outlook improves; German stocks outperform\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global growth stabilizes\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Global trade rebounds; emerging markets benefit\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"New normal\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Stable growth across EU/US; ECB remains dovish\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"ECB tightens monetary policy\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB tightens policy in response to inflation\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Euro strengthens\",\n          \"description\": \"Euro strengthens, hurting exports\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Industrial slowdown\",\n          \"description\": \"German industry reports slower growth\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Bundesbank warns\",\n          \"description\": \"Bundesbank warns of inflation risks\"\n        },\n        {\n          \"id\": \"T1A2.4\",\n          \"title\": \"Consumers cut back\",\n          \"description\": \"German consumers cut back on spending\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Industry opposes ECB policy\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Job cuts, political backlash, delayed consumption\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Markets unstable\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Growth outlook declines; ECB remains hawkish\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Global recession risk rises\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Trade slows; emerging markets struggle\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global downturn\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Recession conditions persist; ECB maintains rate hikes\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n\n[Given Scenario]\nThe total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). The US accounted for the highest diagnosed prevalent cases of eosinophilic esophagitis in 2023, with around 65% of the total diagnosed prevalent cases across the 7MM. \n\nAmong EU4 and the UK, Germany will capture the maximum revenue share, followed by France and UK in 2034. The analysis reveals that a higher diagnosed prevalence of eosinophilic esophagitis is observed in the male gender across the 7MM. \n\nProton Pump Inhibitors have been the cornerstone of eosinophilic esophagitis management. In recent years, therapies like DUPIXENT, EOHILIA, and JORVEZA have been approved for the treatment of EoE in the 7MM countries. \n\nThe pipeline for Eosinophilic Esophagitis is strong, with many candidates like VELSIPITY, TEZSPIRE, ESO-101, Cendakimab, and others. In February 2024, the US FDA approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with EoE. \n\nIn January 2024, US FDA approved DUPIXENT (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with EoE. In September 2024, Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of DUPIXENT (dupilumab) in the European Union for EoE in children down to 1 year of age. \n\nThe market for Eosinophilic Esophagitis is driven by significant unmet needs, particularly in the development of novel treatments and the establishment of comprehensive guidelines for adolescents and adults. Current treatments, like proton pump inhibitors and corticosteroids therapy, manage symptoms but come with serious side effects due to high steroid dosages. \n\nIn 2023, the United States held the largest market share for Eosinophilic Esophagitis among the 7MM, accounting for approximately 75% of the total market. In 2023, DUPIXENT dominated the Eosinophilic Esophagitis therapy market in the United States. However, by 2034, Cendakimab is expected to take the lead, commanding the largest market share. \n\nRegeneron Pharmaceuticals' DUPIXENT (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) pathways and is not an immunosuppressant. It is approved for the treatment of EoE in adults and pediatric patients 12 years and older weighing at least 40 Kg. \n\nCendakimab (CC-93538/RPC4046) is a recombinant humanized, high affinity, selective, anti-IL-13 mAb. RPC4046 binds an IL-13 epitope that prevents its binding to both IL-13R (alpha) 1 and IL-13R (alpha) 2, providing potential efficacy and/or safety advantages. The drug has been granted ODD for the treatment of EoE by the US FDA. \n\nTEZSPIRE (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP. This key epithelial cytokine sits at the top of multiple inflammatory cascades. It is critical in the initiation and persistence of allergic, eosinophilic, and other types of airway inflammation associated with severe asthma, including airway hyperresponsiveness.\n[Output in JSON]\n",
  "response": "```json\n{\n  \"id\": \"T0\",\n  \"title\": \"Current Market Landscape (2023)\",\n  \"description\": \"Eosinophilic Esophagitis (EoE) market valued at USD 1.80 trillion in 7MM, with the US leading at 75% market share. Proton Pump Inhibitors dominate treatment, while DUPIXENT leads the therapy market in the US.\",\n  \"children\": [\n    {\n      \"id\": \"T1A\",\n      \"title\": \"Regulatory Approvals in 2024\",\n      \"date_range\": \"Early 2024\",\n      \"description\": \"US FDA approves EOHILIA (budesonide oral suspension) and DUPIXENT for pediatric EoE. CHMP recommends DUPIXENT expansion in EU.\",\n      \"children\": [\n        {\n          \"id\": \"T1A1\",\n          \"title\": \"Successful EU Approval of DUPIXENT\",\n          \"description\": \"CHMP approves DUPIXENT for children down to 1 year in EU.\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Increased Market Penetration in EU\",\n              \"date_range\": \"Mid 2024 - 2025\",\n              \"description\": \"DUPIXENT gains significant market share in Germany, France, and UK. Regeneron and Sanofi expand distribution networks.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Cendakimab Enters Competitive Market\",\n                  \"date_range\": \"2026\",\n                  \"description\": \"Cendakimab (RPC4046) receives FDA approval for EoE, presenting a direct competitor to DUPIXENT.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Price Wars and Market Share Shifts\",\n                      \"date_range\": \"2027 - 2028\",\n                      \"description\": \"Regulators intervene to prevent excessive pricing. Companies engage in pricing strategies to capture market share.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"Consolidation in Pharma Industry\",\n                          \"date_range\": \"2029\",\n                          \"description\": \"Mergers and acquisitions occur among smaller biotech firms to compete with larger players like Regeneron and AstraZeneca.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6A1\",\n                              \"title\": \"Stable Market Leadership\",\n                              \"date_range\": \"2030 - 2034\",\n                              \"description\": \"Cendakimab secures largest market share by 2034. Regeneron focuses on next-gen therapies and global expansion.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7A1\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors consider long positions in Cendakimab producers and short positions in proton pump inhibitor manufacturers.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                },\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"DUPIXENT Maintains Dominance\",\n                  \"date_range\": \"2026\",\n                  \"description\": \"DUPIXENT shows superior efficacy and safety, retaining its leading market position against emerging therapies.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Expansion into New Indications\",\n                      \"date_range\": \"2027 - 2029\",\n                      \"description\": \"Regeneron expands DUPIXENT into related inflammatory conditions, increasing its revenue streams.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global Market Expansion\",\n                          \"date_range\": \"2030\",\n                          \"description\": \"DUPIXENT enters emerging markets in Asia and Latin America through strategic partnerships.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6A2\",\n                              \"title\": \"Sustained Revenue Growth\",\n                              \"date_range\": \"2031 - 2034\",\n                              \"description\": \"DUPIXENT remains the market leader with diversified applications. Regeneron invests in next-generation biologics.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7A2\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors consider long positions in Regeneron and related biotech ETFs, hedging against proton pump inhibitor market declines.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Delayed EU Approval of DUPIXENT\",\n              \"description\": \"CHMP requests additional data for DUPIXENT approval in EU, delaying market entry.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A3\",\n                  \"title\": \"Competitive Advantage for Early Approvers\",\n                  \"date_range\": \"2025\",\n                  \"description\": \"Companies like Amgen expedite TEZSPIRE development to capture EU market share first.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A3\",\n                      \"title\": \"Increased R&D Investments\",\n                      \"date_range\": \"2026 - 2027\",\n                      \"description\": \"Pharma companies invest heavily in R&D for novel EoE treatments to fill the approval gap.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A3\",\n                          \"title\": \"Emergence of New Therapies\",\n                          \"date_range\": \"2028\",\n                          \"description\": \"TEZSPIRE and ESO-101 receive EU approval, diversifying treatment options.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6A3\",\n                              \"title\": \"Diversified Market Share\",\n                              \"date_range\": \"2029 - 2034\",\n                              \"description\": \"Multiple therapies coexist, reducing dependence on any single treatment. Market becomes more competitive and balanced.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7A3\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors diversify portfolios with stakes in multiple biotech firms, reducing risk associated with single-drug dependence.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                },\n                {\n                  \"id\": \"T3A4\",\n                  \"title\": \"Regulatory Scrutiny Intensifies\",\n                  \"date_range\": \"2025\",\n                  \"description\": \"EU authorities implement stricter guidelines for biologics, impacting approval timelines.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A4\",\n                      \"title\": \"Increased Compliance Costs\",\n                      \"date_range\": \"2026 - 2028\",\n                      \"description\": \"Pharma companies incur higher costs to meet new regulatory standards, affecting profitability.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A4\",\n                          \"title\": \"Market Consolidation\",\n                          \"date_range\": \"2029\",\n                          \"description\": \"Smaller firms struggle with compliance costs, leading to acquisitions by larger entities.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6A4\",\n                              \"title\": \"Dominance of Large Pharma\",\n                              \"date_range\": \"2030 - 2034\",\n                              \"description\": \"A few large pharmaceutical companies control the majority of the EoE treatment market in the EU.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7A4\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors focus on large pharmaceutical companies with established compliance capabilities and diverse portfolios.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A2\",\n          \"title\": \"Regulatory Delays for EOHILIA\",\n          \"description\": \"US FDA requests additional safety data for EOHILIA approval.\",\n          \"children\": [\n            {\n              \"id\": \"T2A3\",\n              \"title\": \"Extended Clinical Trials\",\n              \"date_range\": \"2024 - 2025\",\n              \"description\": \"Manufacturers conduct extended trials to address FDA concerns, delaying market entry.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A5\",\n                  \"title\": \"Opportunity for Competitors\",\n                  \"date_range\": \"2025\",\n                  \"description\": \"Competitors like JORVEZA accelerate their development pipelines to capture market share.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A5\",\n                      \"title\": \"Diversification of Treatment Options\",\n                      \"date_range\": \"2026\",\n                      \"description\": \"Multiple therapies become available, reducing reliance on a single treatment modality.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A5\",\n                          \"title\": \"Enhanced Patient Outcomes\",\n                          \"date_range\": \"2027 - 2034\",\n                          \"description\": \"With more treatment options, patients experience better management of EoE, driving market growth.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6A5\",\n                              \"title\": \"Investment Actions\",\n                              \"date_range\": \"2034\",\n                              \"description\": \"Investors seek opportunities in companies with robust pipelines and diversification strategies.\",\n                              \"children\": []\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T2A4\",\n              \"title\": \"EOHILIA Approval in Late 2025\",\n              \"description\": \"US FDA approves EOHILIA after extended review, entering the market as the first oral therapy.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A6\",\n                  \"title\": \"Market Dynamics Shift\",\n                  \"date_range\": \"2026\",\n                  \"description\": \"EOHILIA captures significant market share due to its oral administration route, preferred by patients.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A6\",\n                      \"title\": \"Competitive Responses\",\n                      \"date_range\": \"2027 - 2028\",\n                      \"description\": \"Competitors enhance their formulations or develop new delivery mechanisms to stay competitive.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A6\",\n                          \"title\": \"Innovation in Drug Delivery\",\n                          \"date_range\": \"2029\",\n                          \"description\": \"Advancements in drug delivery systems improve efficacy and patient adherence, driving market growth.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6A6\",\n                              \"title\": \"Stable and Growing Market\",\n                              \"date_range\": \"2030 - 2034\",\n                              \"description\": \"Continuous innovation sustains market expansion, with multiple effective treatments available.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7A5\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors focus on companies leading in drug delivery innovations and diversified treatment portfolios.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1B\",\n      \"title\": \"Emerging Therapies and Pipeline Development\",\n      \"date_range\": \"2024 - 2034\",\n      \"description\": \"Robust pipeline with candidates like VELSIPITY, TEZSPIRE, ESO-101, and Cendakimab advancing through trials.\",\n      \"children\": [\n        {\n          \"id\": \"T1B1\",\n          \"title\": \"Successful Phase III Trials for VELSIPITY\",\n          \"description\": \"VELSIPITY demonstrates superior efficacy in Phase III trials, pending regulatory submission.\",\n          \"children\": [\n            {\n              \"id\": \"T2B1\",\n              \"title\": \"Regulatory Submission and Approval\",\n              \"date_range\": \"2025 - 2026\",\n              \"description\": \"Submit NDA to FDA and EMA; anticipated approval by mid-2026.\",\n              \"children\": [\n                {\n                  \"id\": \"T3B1\",\n                  \"title\": \"Market Launch of VELSIPITY\",\n                  \"date_range\": \"Late 2026\",\n                  \"description\": \"VELSIPITY launches, gaining rapid adoption due to efficacy and safety profile.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4B1\",\n                      \"title\": \"Regeneron and Competitors Respond\",\n                      \"date_range\": \"2027 - 2028\",\n                      \"description\": \"Increase marketing efforts and invest in R&D to counter VELSIPITY's market impact.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5B1\",\n                          \"title\": \"Enhanced R&D Collaborations\",\n                          \"date_range\": \"2029\",\n                          \"description\": \"Pharma companies form alliances to share R&D costs and accelerate innovation.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6B1\",\n                              \"title\": \"Sustained Innovation Pipeline\",\n                              \"date_range\": \"2030 - 2034\",\n                              \"description\": \"Continuous introduction of novel therapies maintains competitive and dynamic market environment.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7B1\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors target companies with strong innovation pipelines and strategic partnerships.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1B2\",\n          \"title\": \"Delays in TEZSPIRE Development\",\n          \"description\": \"TEZSPIRE faces setbacks in clinical trials, delaying its entry into the EoE market.\",\n          \"children\": [\n            {\n              \"id\": \"T2B2\",\n              \"title\": \"Extended Clinical Trials\",\n              \"date_range\": \"2025 - 2027\",\n              \"description\": \"Additional trials required to demonstrate efficacy and safety, increasing development costs.\",\n              \"children\": [\n                {\n                  \"id\": \"T3B2\",\n                  \"title\": \"Shift in Strategic Focus\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"AstraZeneca and Amgen redirect resources to other promising candidates like ESO-101 and Cendakimab.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4B2\",\n                      \"title\": \"Diversification of Product Portfolio\",\n                      \"date_range\": \"2029 - 2030\",\n                      \"description\": \"Focus on multiple candidates reduces dependency on single therapy outcomes.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5B2\",\n                          \"title\": \"Balanced Market Dynamics\",\n                          \"date_range\": \"2031 - 2034\",\n                          \"description\": \"Multiple effective treatments coexist, catering to diverse patient needs and preferences.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6B2\",\n                              \"title\": \"Investment Actions\",\n                              \"date_range\": \"2034\",\n                              \"description\": \"Investors diversify holdings across multiple biotech firms to capitalize on varied treatment successes.\",\n                              \"children\": []\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1B3\",\n          \"title\": \"Success of Cendakimab in Clinical Trials\",\n          \"description\": \"Cendakimab shows promising results in late-stage trials, positioning it as a strong competitor.\",\n          \"children\": [\n            {\n              \"id\": \"T2B3\",\n              \"title\": \"Regulatory Submissions\",\n              \"date_range\": \"2026 - 2027\",\n              \"description\": \"Submit filings to FDA and EMA, anticipating approvals by late 2027.\",\n              \"children\": [\n                {\n                  \"id\": \"T3B3\",\n                  \"title\": \"Approval and Market Entry\",\n                  \"date_range\": \"Late 2027\",\n                  \"description\": \"Cendakimab approved, capturing significant market share due to its targeted mechanism.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4B3\",\n                      \"title\": \"Regeneron Enhances DUPIXENT\",\n                      \"date_range\": \"2028 - 2029\",\n                      \"description\": \"Regeneron invests in enhancing DUPIXENT's formulation and expands indications to maintain competitiveness.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5B3\",\n                          \"title\": \"Competitive Balance\",\n                          \"date_range\": \"2030 - 2034\",\n                          \"description\": \"Market achieves a balance with multiple leading therapies, fostering innovation and patient choice.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6B3\",\n                              \"title\": \"Investment Actions\",\n                              \"date_range\": \"2034\",\n                              \"description\": \"Investors allocate funds to leading biotech firms with diversified and competitive portfolios.\",\n                              \"children\": []\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1C\",\n      \"title\": \"Policy and Guideline Developments\",\n      \"date_range\": \"2024 - 2034\",\n      \"description\": \"Development of comprehensive guidelines for EoE treatment and management for adolescents and adults.\",\n      \"children\": [\n        {\n          \"id\": \"T1C1\",\n          \"title\": \"Establishment of Global EoE Treatment Guidelines\",\n          \"description\": \"Organizations like WHO and major medical associations release standardized treatment protocols.\",\n          \"children\": [\n            {\n              \"id\": \"T2C1\",\n              \"title\": \"Standardization of Care\",\n              \"date_range\": \"2025 - 2026\",\n              \"description\": \"Healthcare providers adopt standardized guidelines, improving treatment consistency and outcomes.\",\n              \"children\": [\n                {\n                  \"id\": \"T3C1\",\n                  \"title\": \"Insurance Coverage Expansion\",\n                  \"date_range\": \"2027\",\n                  \"description\": \"Insurance companies broaden coverage for approved EoE therapies, increasing patient access.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4C1\",\n                      \"title\": \"Market Growth Accelerates\",\n                      \"date_range\": \"2028 - 2030\",\n                      \"description\": \"Increased access and standardized care drive market expansion and adoption of novel therapies.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5C1\",\n                          \"title\": \"Global Market Integration\",\n                          \"date_range\": \"2031 - 2034\",\n                          \"description\": \"Unified guidelines facilitate global market integration, enhancing cross-border trade and collaboration.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6C1\",\n                              \"title\": \"Sustained Market Expansion\",\n                              \"date_range\": \"2034\",\n                              \"description\": \"Comprehensive guidelines ensure ongoing market growth and stability across regions.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7C1\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors prioritize companies aligned with global guidelines and standards, ensuring compliance and market readiness.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1C2\",\n          \"title\": \"Implementation of Comprehensive EoE Guidelines\",\n          \"description\": \"National health agencies adopt comprehensive guidelines, promoting best practices in EoE management.\",\n          \"children\": [\n            {\n              \"id\": \"T2C2\",\n              \"title\": \"Training and Education Programs\",\n              \"date_range\": \"2025 - 2026\",\n              \"description\": \"Healthcare professionals receive training on new EoE guidelines, enhancing treatment efficacy.\",\n              \"children\": [\n                {\n                  \"id\": \"T3C2\",\n                  \"title\": \"Improved Patient Outcomes\",\n                  \"date_range\": \"2027 - 2028\",\n                  \"description\": \"Standardized treatment leads to better patient management and reduced incidence of complications.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4C2\",\n                      \"title\": \"Increased Demand for Novel Therapies\",\n                      \"date_range\": \"2029 - 2030\",\n                      \"description\": \"Enhanced guidelines recognize the benefits of novel therapies, driving demand beyond traditional treatments.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5C2\",\n                          \"title\": \"Market Diversification\",\n                          \"date_range\": \"2031 - 2034\",\n                          \"description\": \"Diverse treatment options meet varied patient needs, fostering a dynamic and resilient market.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6C2\",\n                              \"title\": \"Sustained Innovation and Growth\",\n                              \"date_range\": \"2034\",\n                              \"description\": \"Ongoing adherence to guidelines and continuous innovation ensure sustained market growth.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7C2\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors focus on companies leading in guideline-aligned therapies and those contributing to improved patient outcomes.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1D\",\n      \"title\": \"Economic and Market Factors\",\n      \"date_range\": \"2024 - 2034\",\n      \"description\": \"Economic conditions and market dynamics influencing the EoE treatment landscape.\",\n      \"children\": [\n        {\n          \"id\": \"T1D1\",\n          \"title\": \"Global Economic Stability\",\n          \"description\": \"Stable economic growth supports healthcare investments and patient affordability.\",\n          \"children\": [\n            {\n              \"id\": \"T2D1\",\n              \"title\": \"Increased Healthcare Funding\",\n              \"date_range\": \"2025 - 2026\",\n              \"description\": \"Governments and private sectors allocate more funds to chronic disease management, including EoE.\",\n              \"children\": [\n                {\n                  \"id\": \"T3D1\",\n                  \"title\": \"Expansion of Healthcare Infrastructure\",\n                  \"date_range\": \"2027 - 2028\",\n                  \"description\": \"Enhanced infrastructure supports broader access to EoE treatments and diagnostic services.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4D1\",\n                      \"title\": \"Market Expansion in Emerging Economies\",\n                      \"date_range\": \"2029 - 2030\",\n                      \"description\": \"Emerging markets increase their healthcare spending on specialized treatments like EoE therapies.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5D1\",\n                          \"title\": \"Diversified Revenue Streams for Pharma Companies\",\n                          \"date_range\": \"2031 - 2034\",\n                          \"description\": \"Pharma companies benefit from global market diversification, mitigating regional economic fluctuations.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6D1\",\n                              \"title\": \"Sustained Market Growth\",\n                              \"date_range\": \"2034\",\n                              \"description\": \"Stable economic conditions ensure ongoing investment in EoE treatments and market resilience.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7D1\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors allocate capital to globally diversified pharma firms with strong presence in emerging markets.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1D2\",\n          \"title\": \"Economic Downturns\",\n          \"description\": \"Potential economic recessions impacting healthcare budgets and patient spending.\",\n          \"children\": [\n            {\n              \"id\": \"T2D2\",\n              \"title\": \"Budget Cuts in Healthcare\",\n              \"date_range\": \"2025 - 2026\",\n              \"description\": \"Governments reduce healthcare spending, affecting funding for specialized treatments.\",\n              \"children\": [\n                {\n                  \"id\": \"T3D3\",\n                  \"title\": \"Shift to Cost-Effective Treatments\",\n                  \"date_range\": \"2027\",\n                  \"description\": \"Healthcare providers prioritize cost-effective treatments over premium therapies.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4D3\",\n                      \"title\": \"Pressure on Pharma Pricing Strategies\",\n                      \"date_range\": \"2028 - 2029\",\n                      \"description\": \"Pharma companies negotiate lower prices or offer tiered pricing to maintain market access.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5D3\",\n                          \"title\": \"Innovation Focus Shifts to Cost Reduction\",\n                          \"date_range\": \"2030 - 2032\",\n                          \"description\": \"R&D focuses on developing affordable therapies without compromising efficacy.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6D3\",\n                              \"title\": \"Resilient Market Segments\",\n                              \"date_range\": \"2033 - 2034\",\n                              \"description\": \"Cost-effective therapies maintain market stability despite economic pressures.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7D3\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors seek companies with strong cost-management strategies and affordable treatment options.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T2D4\",\n              \"title\": \"Reduced Patient Spending\",\n              \"description\": \"Patients prioritize essential expenses, potentially delaying or foregoing EoE treatments.\",\n              \"children\": [\n                {\n                  \"id\": \"T3D4\",\n                  \"title\": \"Shift to Over-the-Counter Treatments\",\n                  \"date_range\": \"2027 - 2028\",\n                  \"description\": \"Increased demand for OTC treatments like proton pump inhibitors as patients seek affordable options.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4D4\",\n                      \"title\": \"Competitive Pricing Pressure\",\n                      \"date_range\": \"2029 - 2030\",\n                      \"description\": \"Pharma companies lower prices of novel therapies to remain competitive against OTC alternatives.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5D4\",\n                          \"title\": \"Market Segmentation\",\n                          \"date_range\": \"2031 - 2034\",\n                          \"description\": \"Distinct market segments emerge for premium and cost-effective treatments, catering to varied patient budgets.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6D4\",\n                              \"title\": \"Stable Dual-Track Market\",\n                              \"date_range\": \"2034\",\n                              \"description\": \"Both premium therapies and cost-effective treatments coexist, ensuring market resilience.\",\n                              \"children\": [\n                                {\n                                  \"id\": \"T7D4\",\n                                  \"title\": \"Investment Actions\",\n                                  \"date_range\": \"2034\",\n                                  \"description\": \"Investors balance portfolios with stakes in both premium biotech firms and companies offering affordable treatments.\",\n                                  \"children\": []\n                                }\n                              ]\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n```",
  "processing_time": 101.7883231639862,
  "estimated_prompt_tokens": 2733,
  "response_tokens": 5921
}